participation (e.g., dialysis for end‐stage renal disease). For this study, we selected participants who met criteria similar to those enrolled in recent clinical trials of anti‐amyloid antibodies 1 , 2 : participants had a clinical diagnosis of AD dementia in accordance with standard criteria with a global CDR score of 0.5 or 1 and confirmation of amyloid pathology as determined by CSF Aβ42/40 <0.067322 or amyloid PET Centiloid (CL) >2023 within 1 year of the clinical AD diagnosis. In addition, all participants were 60 years of age or older at baseline and had at least one follow‐up clinical assessment within 5 years of the baseline visit at which they were diagnosed with AD dementia. We used data from all assessments within this time period.
